Phase 1 3 trials
Phase 1
NCT04040699 Sep 2019 → Sep 2022 HER2 positive breast carcinoma Peking University
Completed
No outcome recorded
Phase 1
NCT03733951 Dec 2018 → Jan 2023 cancer , lymphoma Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Completed
No outcome recorded
Phase 1
NCT03529526 May 2018 → Oct 2019 cancer Alphamab (Australia) Co Pty Ltd.
Unknown
No outcome recorded
Phase 1/2 6 trials
Phase 1/2
NCT05832892 Nov 2023 → Nov 2024 neoplastic disease or syndrome Shanghai Zhongshan Hospital
Unknown
No outcome recorded
Phase 1/2
NCT05827796 Dec 2022 → Dec 2025 overdue malignant pancreatic neoplasm InxMed (Shanghai) Co., Ltd.
Recruiting
No outcome recorded
Phase 1/2
NCT04984668 Nov 2021 → Apr 2025 cancer Suzhou Kintor Pharmaceutical Inc
Unknown
No outcome recorded
Phase 1/2
NCT04601610 Jun 2021 → May 2022 hepatocellular carcinoma Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Terminated
No outcome recorded
Phase 1/2
NCT04612712 Jan 2021 → Jun 2022 —
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Terminated
No outcome recorded
Phase 1/2
NCT03872791 May 2019 → Aug 2022 triple-negative breast carcinoma Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Completed
No outcome recorded
Phase 2 15 trials
Phase 2
NCT05985109 Oct 2023 → Dec 2026 expected colorectal cancer Peking University Cancer Hospital & Institute
Recruiting
No outcome recorded
Phase 2
NCT06099821 Oct 2023 → Dec 2026 expected digestive system cancer Peking University Cancer Hospital & Institute
Recruiting
No outcome recorded
Phase 2
NCT06023758 Sep 2023 → Sep 2025 overdue carcinoma Peking University
Recruiting
No outcome recorded
Phase 2
NCT05985707 Aug 2023 → Dec 2026 expected carcinoma Peking University Cancer Hospital & Institute
Not yet recruiting
No outcome recorded
Phase 2
NCT06834399 Apr 2023 → Dec 2024 colorectal cancer Zhejiang Raygene Pharmaceuticals Co., Ltd
Terminated
No outcome recorded
Phase 2
NCT05420220 Jul 2022 → Dec 2024 non-small cell lung carcinoma Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Completed
No outcome recorded
Phase 2
NCT04925947 Dec 2021 → May 2023 thymic carcinoma Weill Medical College of Cornell University
Terminated
No outcome recorded
Phase 2
NCT04521179 Dec 2020 → Jan 2022 —
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Completed
No outcome recorded
Phase 2
NCT04469725 Dec 2020 → Jul 2023 thymic carcinoma Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Terminated
No outcome recorded
Phase 2
NCT04542837 Sep 2020 → Feb 2022 hepatocellular carcinoma Peking University Cancer Hospital & Institute
Completed
No outcome recorded
Phase 2
NCT04165993 Dec 2019 → May 2021 breast cancer Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Unknown
No outcome recorded
Phase 2
NCT04054531 Sep 2019 → Mar 2021 non-small cell lung carcinoma Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Unknown
No outcome recorded
Phase 2
NCT03925870 Jun 2019 → Aug 2021 esophageal squamous cell carcinoma Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Completed
No outcome recorded
Phase 2
NCT03927495 May 2019 → Jun 2021 esophageal squamous cell carcinoma Shanghai Chest Hospital
Unknown
No outcome recorded
Phase 2
NCT03838848 May 2019 → Jul 2022 non-small cell lung carcinoma Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Terminated
No outcome recorded
Show 5 more trials Phase 2/3 2 trials
Phase 2/3
NCT06020352 Aug 2023 → Jul 2025 non-small cell lung carcinoma Shanghai Pulmonary Hospital, Shanghai, China
Unknown
No outcome recorded
Phase 2/3
NCT05001724 Oct 2021 → Feb 2023 non-small cell lung carcinoma Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Terminated
No outcome recorded
Phase 3 2 trials
Phase 3
NCT05149326 Jan 2022 → Apr 2024 pancreatic ductal adenocarcinoma Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Unknown
No outcome recorded
Phase 3
NCT04474119 Sep 2020 → Aug 2022 non-small cell squamous lung carcinoma Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Unknown
No outcome recorded